Meera Sheffrin1, Yinghui Miao1, W John Boscardin1,2, Michael A Steinman1. 1. Division of Geriatrics, University of California at San Francisco and San Francisco Veterans Affairs Medical Center, San Francisco, California. 2. Department of Epidemiology and Biostatistics, University of California at San Francisco, San Francisco, California.
Abstract
OBJECTIVES: To determine whether initiation of cholinesterase inhibitors is associated with significant weight loss in a real-word clinical setting. DESIGN:Retrospective cohort study from 2007 to 2010 comparing weight loss in individuals with dementia newly prescribed cholinesterase inhibitors and those newly prescribed other chronic medications. SETTING: National Veterans Affairs data. PARTICIPANTS: Individuals aged 65 and older with a diagnosis of dementia who received a new prescription for a cholinesterase inhibitor or other new chronic medication. MEASUREMENTS: The primary outcome was time to 10-pound weight loss over 12 months. Propensity score matching was used to control for the likelihood of receiving a cholinesterase inhibitor based on baseline characteristics. Data were analyzed in a priori defined subgroups according to age, comorbid burden, and initial weight. RESULTS: Of 6,504 individuals that met study criteria, 1,188 started on cholinesterase inhibitors were matched to 2,189 started on other medications. The propensity-matched cohorts were well balanced on baseline covariates. Participants initiated on cholinesterase inhibitors had a higher risk of weight loss than matched controls at 12 months (hazard ratio = 1.23, 95% confidence interval (CI) = 1.07-1.41). At 12 months, 29.3% of participants taking cholinesterase inhibitors had experienced weight loss, compared with 22.8% of nonusers, corresponding to a number needed to harm of 21.2 (95% CI = 12.5-71.4) over 1 year. There were no significant differences in the risk of weight loss within subgroups. CONCLUSION: These results are consistent with the available data from randomized controlled trials. Clinicians should consider the risk of weight loss when prescribing cholinesterase inhibitors.
RCT Entities:
OBJECTIVES: To determine whether initiation of cholinesterase inhibitors is associated with significant weight loss in a real-word clinical setting. DESIGN: Retrospective cohort study from 2007 to 2010 comparing weight loss in individuals with dementia newly prescribed cholinesterase inhibitors and those newly prescribed other chronic medications. SETTING: National Veterans Affairs data. PARTICIPANTS: Individuals aged 65 and older with a diagnosis of dementia who received a new prescription for a cholinesterase inhibitor or other new chronic medication. MEASUREMENTS: The primary outcome was time to 10-pound weight loss over 12 months. Propensity score matching was used to control for the likelihood of receiving a cholinesterase inhibitor based on baseline characteristics. Data were analyzed in a priori defined subgroups according to age, comorbid burden, and initial weight. RESULTS: Of 6,504 individuals that met study criteria, 1,188 started on cholinesterase inhibitors were matched to 2,189 started on other medications. The propensity-matched cohorts were well balanced on baseline covariates. Participants initiated on cholinesterase inhibitors had a higher risk of weight loss than matched controls at 12 months (hazard ratio = 1.23, 95% confidence interval (CI) = 1.07-1.41). At 12 months, 29.3% of participants taking cholinesterase inhibitors had experienced weight loss, compared with 22.8% of nonusers, corresponding to a number needed to harm of 21.2 (95% CI = 12.5-71.4) over 1 year. There were no significant differences in the risk of weight loss within subgroups. CONCLUSION: These results are consistent with the available data from randomized controlled trials. Clinicians should consider the risk of weight loss when prescribing cholinesterase inhibitors.
Authors: C Ballard; M Sauter; P Scheltens; Y He; F Barkhof; E C W van Straaten; W M van der Flier; C Hsu; S Wu; R Lane Journal: Curr Med Res Opin Date: 2008-07-31 Impact factor: 2.580
Authors: Sandeep R Das; Linda S Kinsinger; William S Yancy; Anthea Wang; Eileen Ciesco; Mary Burdick; Steven J Yevich Journal: Am J Prev Med Date: 2005-04 Impact factor: 5.043
Authors: Martin Farlow; Felix Veloso; Margaret Moline; Jane Yardley; Elimor Brand-Schieber; Francesco Bibbiani; Heng Zou; Timothy Hsu; Andrew Satlin Journal: BMC Neurol Date: 2011-05-25 Impact factor: 2.474
Authors: Brenna N Renn; Ali Abbas Asghar-Ali; Stephen Thielke; Angela Catic; Sharyl R Martini; Brian G Mitchell; Mark E Kunik Journal: Am J Geriatr Psychiatry Date: 2017-10-10 Impact factor: 4.105